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a  b  s  t  r  a  c  t
Mycobacterium  tuberculosis  is an  accomplished  intracellular  pathogen,  particularly  within  the
macrophage  and this  is  of  the  utmost  importance  in  the  host-pathogen  stand-off  observed  in the granu-
loma  during  latent  tuberculosis.  Contact  with  innate  immune  molecules  is one  of the  primary  interactions
that  can occur  with  the  pathogen  M. tuberculosis  once  inhaled.  Complement  proteins  may  play  a role  in
facilitating  M.  tuberculosis  interactions  with  macrophages.  Here,  we  demonstrate  that  factor  H, a  comple-
ment regulatory  protein  that  down-regulates  complement  alternative  pathway  activation,  binds  directly
to the  model  organism  M.  bovis  BCG.  Binding  of  factor  H  reaches  saturation  at 5–10 g of  factor  H/ml,  well
below  the  plasma  level.  C4 binding  protein  (C4BP)  competed  with  factor  H  for binding  to  mycobacteria.
Factor  H was  also  found  to inhibit  uptake  of M.  bovis  BCG  by  THP-1  macrophage  cells  in  a dose-dependent
manner.  Real-time  qPCR  analysis  showed  stark  differential  responses  of  pro- and  anti-inﬂammatory
cytokines  during  the  early  stages  of phagocytosis,  as evident  from  elevated  levels  of  TNF-,  IL-1  and
IL-6,  and  a concomitant  decrease  in IL-10,  TGF-  and  IL-12  levels,  when  THP-1:BCG  interaction  tookytokine place  in  the  presence  of  factor  H.  Our  results  suggest  that  factor  H  can  interfere  with  mycobacterial  entry
into  macrophages  and  modulate  inﬂammatory  cytokine  responses,  particularly  during  the  initial  stages
of infection,  thus  affecting  the  extracellular  survival  of the  pathogen.  Our  results  offer novel  insights
into  complement  activation-independent  functions  of  factor  H  during  the  host-pathogen  interaction  in
tuberculosis.
© 2016  The  Author(s).  Published  by  Elsevier  GmbH.  This  is  an open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Tuberculosis (TB) remains a major global health problem with
he majority of cases of active TB disease and TB-related deaths
ccurring in developing countries (Zumla et al., 2013). Currently,
here are 8.7 million new cases of active TB and 1.4 million deaths
er year, with one in every three people infected worldwide with
Abbreviations: TB, tuberculosis; BCG, Bacillus Calmette-Guerin; C4BP, C4b-
inding protein; CCP, complement control protein; CR, complement receptors; M++,
ivalent metal ions; MAC, membrane attack complex.
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171-2985/© 2016 The Author(s). Published by Elsevier GmbH. This is an open access ar
d/4.0/).latent TB infection (Zumla et al., 2013). Once the causative agent
Mycobacterium tuberculosis has infected the host through aerosol
inhalation, it is able to evade and circumvent immune responses
allowing it to establish a long-term latent infection through its abil-
ity to persist as an intracellular pathogen within phagocytes. M.
tuberculosis prevents phagosomal maturation and modulates acid-
ity within the phagolysosome, resulting in intracellular survival of
the pathogen within phagocytes for an extended period of time,
thus establishing a life-long infection (Gupta et al., 2012). During
latency, M. tuberculosis resides within a granuloma, a dense collec-
tion of immune cells that is a key pathological feature of TB which
not only limits the growth of the pathogen, but also provides a niche
from which the pathogen can reactivate (Ehlers and Schaible, 2012).
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Fig. 1. Divalent metal ions increase the binding of human factor H to M. bovis BCG. (a) Factor H binding to mycobacteria in 10 mM HEPES, 60 mM NaCl, 100 g/ml hen
ovalbumin pH 7.5 containing either 0.5 mM EDTA or 0.5 mM CaCl2/0.5 mM MgCl2. Serial dilutions of factor H were added to the wells containing mycobacteria followed
by  mouse mAb  anti-factor H, anti-mouse IgG conjugated with alkaline phosphatase. Maltose binding protein (MBP) was used as a negative control. Assay is conducted in
quadruplicate. Error bars represent ± standard deviation. (b) To conﬁrm binding results, ﬂuorescence microscopy was performed to show binding of factor H at different
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toncentrations to M.  bovis BCG cells. Bacterial cells were incubated with either A) 
MBP)  (used as a negative control). Mouse anti-human factor H (MRCOX23) was u
econdary antibody. Scale bar, 50 m.
Although M.  tuberculosis is known to interact with components
f the innate immunity such as toll-like receptors, complement,
urfactant proteins SP-A and SP-D (Tsolaki, 2009), the initial
tages of TB pathogenesis remain poorly understood. The com-
lement system is a key player in innate immunity, providing
rotection against pathogens without the need for previous expo-
ure and/or immunization, in addition to potentiating adaptive
mmunity (Carroll and Sim, 2011). Complement is activated upon
ncounter with pathogens via one or more of three pathways: clas-
ical, lectin, and alternative. Activation of complement by any of
he three pathways results in the formation of a C3 convertase and/ml, B) 5 g/ml, C) 10 g/ml of factor H or D) 10 g/ml of Maltose binding protein
 the primary antibody and goat anti-mouse conjugated with AlexaFluor488 as the
the formation of C3b, which opsonises pathogens and initiates a
number of immune mechanisms, including the generation of the
lytic membrane attack complex (MAC). The complement system
is tightly regulated by several inhibitor proteins that are either
surface-bound or present in the ﬂuid-phase. A key regulator of
complement activation is factor H, which regulates the alternative
pathway (Sim et al., 1993) and the classical pathway (Kishore and
Sim, 2012). Human factor H is a 155 kDa elongated glycoprotein and
can bind simultaneously to C3b and suitable charge-cluster ligands
on complement alternative pathway activator and non-activator
surfaces (Kuhn and Zipfel, 1996).
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rig. 2. Human C4BP from serum binds immobilised M. bovis BCG in EDTA and i
ycobacteria. Binding of C4BP was  determined using anti-C4BP polyclonal antibod
onducted in quadruplicate. Error bars represent ± standard deviation.
Many bacteria have evolved mechanisms to evade comple-
ent, which include proteolytic cleavage of complement proteins,
aving their own complement inhibitors (Rooijakkers and van
trijp, 2007), or binding of host’s complement regulatory proteins.
ince factor H is a soluble down-regulator of the complement
ystem, its sequestration on the bacterial cell surfaces may  help
athogens resist complement attack. For instance, binding of factor
 and/or C4 binding protein (C4BP), another complement regula-
or, was shown to decrease C3b and C4b deposition on the surface
f Streptococci and reduce phagocytosis by macrophages (Thern
t al., 1995). Factor H binds directly to many bacterial species
.g Yersinia, Hemophilus, Borrelia and Streptococcus (China et al.,
993; Hallstrom et al., 2008; Hellwage et al., 2001; Horstmann et al.,
988).
M.  tuberculosis is highly specialised at residing within phago-
ytes and may  exploit complement proteins to gain entry into
acrophages. Although it has been shown that M.  tuberculosis can
ctivate both the classical and the alternative pathways (Ferguson
t al., 2004), it is not clear how the pathogen uses complement
roteins in TB pathogenesis. M.  tuberculosis has been shown to
ind to complement receptors CR1, CR3 and CR4 and gain entry
nto macrophages (Schlesinger et al., 1990). Enhanced phagocy-
osis of M.  tuberculosis by human alveolar and monocyte-derived
acrophages is due to opsonization by C3 (Hirsch et al., 1994).
owever, CR3 is not the dominant route for M.  tuberculosis to gain
ccess inside the phagocyte (Hu et al., 2000; Schlesinger et al.,
990). We  have also previously shown multiple routes of com-
lement activation by Mycobacterium bovis BCG which directly
ctivates the classical, lectin and alternative pathways, resulting
n direct binding of C3b onto the mycobacterial surface (Carroll
t al., 2009). M.  bovis BCG was also shown to bind factor H, suggest-
ng a possible regulation of complement activation on the bacterial
urface (Carroll et al., 2009).
The aim of the present study was to investigate further the role
f factor H in TB pathogenesis, by using the model organism M.
ovis BCG. We  show that factor H may  have functions which are
istinct from its role as a regulator of complement activation. Puri-
ed human factor H binds to the surface of mycobacterial cells, and
nhibits uptake of M.  bovis BCG by macrophages in a dose dependent
anner. Factor H: mycobacteria interaction also alters the pro-
nd anti-inﬂammatory cytokine responses of macrophages, indi-
ating that factor H may  play a role in shaping the initial immune
esponse against mycobacteria. This study highlights novel non-+ Mg2+. Different concentrations of serum (as a source of C4BP) were added to
P-depleted serum was used as negative control for binding speciﬁcity. Assays were
complement-related roles of factor H in the initial stages of TB
infection. It is likely that factor H has an important role to play
in inﬂuencing cellular immunity during latent TB infection.
2. Materials and methods
2.1. Proteins, serum and antibodies
Human factor H was  puriﬁed from plasma as described previ-
ously (Sim et al., 1993), using a monoclonal anti-factor H column.
C4BP-depleted human serum was  prepared as described by Sim
et al. (Sim et al., 1981). Rabbit anti-human factor H and anti-
human C4BP polyclonal antibodies were generated within the MRC
Immunochemistry Unit, Oxford.
2.2. Mycobacterial cell culture
M. bovis BCG (Pasteur strain) was  grown in liquid culture using
Middlebrook 7H9 media (Sigma-Aldrich), supplemented with 0.2%
(v/v) glycerol, 0.05% (v/v) Tween-80, and 10% (v/v) albumin-
dextrose-catalase (ADC) (BD BBL, Becton Dickinson). Cultures
were incubated at 37◦C with agitation (∼120 rpm) for 7–10 days
until the bacteria had reached the exponential growth phase
(OD600nm = 0.80–1.00), which is equivalent to 0.8–1 × 109 bacte-
ria/ml.
2.3. THP-1 cell culture
THP-1 macrophage cells derived from a human acute mono-
cyte leukemia cell line (ATCC TIB-202) were cultured in complete
RPMI-1640 (Gibco) (cRPMI) consisting of 10% (v/v) fetal bovine
serum (FBS) (Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich),
100 U/ml penicillin (Sigma-Aldrich), 100 g/ml streptomycin
(Sigma-Aldrich) and 1 mM sodium pyruvate (Sigma-Aldrich) and
left to grow in 5% CO2 incubator at 37◦C for approximately 3 days
before passaging. To count cells and assess cell death, equal vol-
umes of cell suspension and Trypan Blue (0.4% w/v solution)
were mixed and cells were counted using a haemocytometer with
Neubauer rulings. Cells were then re-suspended in cRPMI.
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Fig. 3. Binding of C4BP to the surface of M.  bovis BCG in the presence of different concentrations of factor H. M.  bovis BCG-coated wells were incubated with 5% human
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.4. Assay for measuring puriﬁed human factor H binding to
ycobacteria
Mycobacterial cells were harvested and washed in PBS and the
oncentration was adjusted to 1.25 × 109 cells/ml in PBS by mea-
uring the OD600nm (using the approximation that an OD600nm = 1
s equivalent to 1 × 109 cell/ml). Then, 200 l of M. bovis BCG bac-
erial suspension was dispensed into each well of a 96-well ELISA
late (MaxisorbTM, Nunc). Plates were incubated at 37◦C for 2 h, or
◦C overnight and washed with buffer I containing 10 mM HEPES,
0 mM NaCl, 50 g/ml hen ovalbumin (Sigma), pH 7.5. Wells were
locked for 2 h at 37◦C with buffer I containing 10% w/v milk pow-
er (Marvel Dried Milk)
Serial two-fold dilutions of puriﬁed factor H were added, (maxi-
um concentration 15 g/ml, 100 l/well, in 10 mM HEPES, 60 mM
aCl, 0.5 mM EDTA, 100 g/ml hen ovalbumin pH 7.5) and incu-
ated for 2 h at room temperature. Wells were washed 3 times
ith the same buffer. Then, MRCOX23 mouse anti-human factor
 antibody (Sim et al., 1983) in the same buffer (2 g in 100 l)
as added to the wells and incubated for 1 h h at room temperature.
lates were washed an additional 3 times and incubated with sheep
nti-mouse IgG-alkaline phosphatase conjugate (Sigma-Aldrich,
A3562), diluted 1/5000 in the same buffer. The substrate p-
itrophenol phosphate (buffered tablets, Sigma-Aldrich, #N7660)
as then added to each well and the colour was  read at 405 nm.
dditional assays were also performed, using the 10 mM HEPES,
0 mM NaCl buffer but with 0.5 mM CaCl2, 0.5 mM MgCl2, instead
f EDTA. All assays were performed in quadruplicate.
.5. Fluorescence microscopy
M.  bovis BCG bacteria (approximately 106 cells) were spotted on
oly-l-lysine coated microscope slides and incubated at 37◦C for
ells to adhere. After washing twice with PBS, bacterial cells were
hen ﬁxed with paraformaldehyde for 10 min. Slides were washed
ve times with PBS and then incubated at 37◦C for 2 h with 2.5, 5 or
0 g/ml of factor H, or 10 g/ml of maltose binding protein (neg-
tive control) in 10 mM HEPES, 60 mM NaCl, 0.5 mM CaCl2, 0.5 mM
gCl2, 100 g/ml hen ovalbumin, pH 7.5. Slides were washed ﬁvector H were added. Binding of C4BP was determined using anti-C4BP polyclonal
hout 15 g/ml of added factor H. Assay was conducted in quadruplicate. Error bars
times with PBS, and then the primary antibody (MRCOX23 mouse
anti-human factor H) added at 1/500 dilution and incubated for
30 min  at room temperature. After washing ﬁve times with PBS,
goat anti-mouse conjugated with AlexaFluor488 was added as the
secondary antibody and incubated for 30 mins at room tempera-
ture. Slides were then washed ﬁve times with PBS and mounted
with antifade (Citiﬂuor AF3) PBS solution and viewed using a Leica
DM4000 Fluorescence microscope. Images were processed using
Image J (http:\\imagej.nih.gov/ij).
2.6. C4BP binding assay
To examine binding of C4BP to mycobacteria, microtitre wells
were coated with M. bovis BCG, washed and blocked as described
above. Two-fold serial dilutions of normal human serum or C4BP-
depleted human serum were added into the wells in the HEPES
buffer containing EDTA or Ca2+/Mg2+ as described earlier and incu-
bated for 2 h at room temperature prior to washing and addition of
1/1000 dilution of rabbit anti-C4BP polyclonal antiserum, diluted in
the appropriate buffer. Next, goat anti-(rabbit IgG)-alkaline phos-
phatase conjugate (1/5000 dilution; Sigma Aldrich, # A3687) and
substrate p-nitrophenol phosphates were added and the plate was
read at 405 nm. Assays were performed in duplicate.
To test whether C4BP competes with factor H for its binding sites
on the mycobacterial surface, we  tested the binding of C4BP (from
serum) to the surface of M. bovis BCG in the presence and absence of
increasing concentrations of factor H in buffer with Ca2+/Mg2+. An
ELISA plate was  coated with M. bovis BCG and incubated (2 h, room
temperature) with 5% human serum (as a source of C4BP), or 5%
human serum containing added puriﬁed factor H (0.25–15 g/ml).
Bound C4BP was  then detected using anti-C4BP polyclonal anti-
body. Assays were performed in quadruplicate.
2.7. Phagocytosis assay50 ml  culture of M. bovis BCG were harvested at mid  exponen-
tial phase (OD600nm = 1) and were centrifuged at 1000g for 10 min
at 4◦C. The cell pellet was  re-suspended in 50 ml  of 7H9 growth
medium (with 10% ADC, 0.05% v/v Tween-80 and 0.2% v/v glycerol).
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Fig. 4. Effect of factor H on the phagocytosis of M.  bovis BCG by THP-1 cells. M. bovis BCG were pre-incubated with factor H at concentrations of 0, 2 and 20 g/ml, and then
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CFUs).  The input value was the starting number of untreated M. bovis BCG added t
his mycobacterial culture was then placed into three microfuge
ubes and treated with either 2 or 20 g/ml of puriﬁed factor H,
r left untreated and incubated for 2 h at room temperature. The
ell suspension was washed once in growth medium before re-
uspending in RPMI-1640 containing 0.05% Tween-80 but without
BS, penicillin and streptomycin. 200 l of the mycobacterial sus-
ension was added to each well of THP-1 cells, as described below.
ycobacterial concentration was adjusted to give approximate
acteria: macrophage ratio of 10:1. To obtain an estimated input
umber of mycobacteria, 4 serial 1/10 dilutions were made and
0 l of the concentrated mycobacterial suspension and diluted
uspensions were spotted on to 7H10 media (Sigma-Aldrich) agar
ells in 24-well plates. The plates were secured with paraﬁlm tape
nd wrapped in aluminum foil to prevent dehydration, inverted
nd incubated at 37◦C for up to 14 days before counting the colony
orming units (CFUs).
THP-1 cells were counted and adjusted to 1 × 106 cells/well (in
.8 ml)  in wells of a 24-well plate. In order to induce adherence onto
he wells, THP-1 cells in RPMI-1640 without FBS, penicillin or strep-
omycin were differentiated into macrophages by adding 50 ng/ml
f phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich #P1585)
nd left to settle for at least 30 min  before adding 200 l volume
f bacterial culture (to give 1 × 107 bacteria/ml). Plates were gen-
ly swirled, secured with micropore tape and incubated in 5% CO2
t 37◦C for up to 6 h in order to allow mycobacterial uptake by
he macrophages. THP-1 cells were collected at 15 min, 30 min,
5 min, 1 h, 2 h and 6 h. Plates were swirled gently to re-suspend
ycobacteria from the bottom of the well and the medium was
hen removed to discard non-ingested bacteria and the THP-1 cells
ere washed once with FBS/antibiotic-free RPMI. THP-1 cells were
ifted after adding 1 ml  of 0.25% trypsin to the wells and incubated
or 10 min  at 37◦C using 1.5 ml  microfuge tubes and centrifuged at
000g for 10 min  at 4◦C. In order to release the ingested mycobacte-
ia, THP-1 cells were lysed by re-suspending the cell pellets in 1 ml
f sterile water followed by a series of vortex-mixing for 10 min  at
oom temperature. 24-well plates containing 2 ml  solid 7H10 agar
er well were prepared in advance. Four serial 1/10 dilutions of
he cell lysate were made and 10 l of the concentrated mycobac-easured by plating lysate on 7H10 media in order to obtain colony forming units
HP-1 cells, pre-phagocytosis.
terial suspension and diluted suspensions from each time-point
were spotted onto the 7H10 agar wells in 24-well plates. The 24-
well plates were secured with paraﬁlm and wrapped in aluminum
foil, inverted and incubated at 37◦C for 14 days as described above.
Wells were photographed after approximately 2 weeks of incuba-
tion as described (Theus et al., 2004), and the CFU counted.
2.8. Total RNA preparation and cDNA synthesis
THP-1 cell pellets were collected and lysed as described above.
RNA extraction was  performed on the pellets using the GenElute
Mammalian Total RNA Puriﬁcation Kit (Sigma-Aldrich) according
to the manufacturer’s protocol. Samples were then treated with
DNase (Sigma-Aldrich) to remove any contaminating DNA accord-
ing to the manufacturer’s protocol. Samples were heated at 70◦C
for 10 min  to inactivate both the DNase I and the RNase, and sub-
sequently chilled on ice. The amount of RNA was  measured using
a NanoDrop 2000/2000c spectrophotometer (Thermo Fisher Scien-
tiﬁc) at 260 nm and the ratio of absorbance at 260 nm and 280 nm
was used to assess the purity of the RNA. cDNA was synthesized
using High Capacity RNA to cDNA Kit (Applied Biosystems) follow-
ing the manufacturer’s protocol.
2.9. Primers for cytokines
Primer sequences were designed and analyzed for speciﬁcity
using the nucleotide Basic Local Alignment Search Tool and Primer-
BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The following
primers were used: 18 S forward (5′-ATGGCCGTTCTTAGTTGGTG-
3′) and 18 S reverse (5′-CGCTGAGCCAGTCAGTGTAG-3′);
IL-1  ˇ forward (5′-GGACAAGCTGAGGAAGATGC-3′) and
IL-1  ˇ reverse (5′-TCGTTATCCCATGTGTCGAA-3′); IL-6
forward (5′-GAAAGCAGCAAAGAGGCACT-3′) and IL-6
reverse (5′-TTTCACCAGGCAAGTCTCCT-3′); IL-10 for-
ward (5′-TTACCTGGAGGAGGTGATGC-3′) and IL-10
reverse (5′-GGCCTTGCTCTTGTTTTCAC-3′); IL-12 for-
ward (5′-AACTTGCAGCTGAAGCCATT-3′) and IL-12
reverse (5′-GACCTGAACGCAGAATGTCA-3′); TGF-  ˇ for-
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Fig. 5. Temporal expression of cytokines by THP-1 cells incubated with M. bovis BCG and different concentrations of factor H. (a) TNF-; (b) IL-1; (c) IL-6; (d) IL-10; (e)
TGF-  and (f) IL-12. qPCR analysis of the expression of cytokines at the following time-points: 15, 30, 45, 60, 120 and 360 mins (not shown along the x-axis) was carried
out.  The calibrator sample used was THP-1 cells without M. bovis BCG and 0 g/ml of factor H. The data was normalized to 18 S rRNA gene expression which was  used as an
endogenous control. Assays were conducted in triplicate. The RQ value was  calculated using the formula: RQ = 2−Ct. Error bars represent ± standard error of the mean. A
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n-way  ANOVA was  performed on the data to compare differences in expression for 
).  All comparisons are statistically signiﬁcant (p ≤ 0.01), except where shown (ns:
ard (5′-GTACCTGAACCCGTGTTGCT-3′) and TGF-ˇ
everse (5′-GTATCGCCAGGAATTGTTGC-3′); TNF-  ˛ forward
5′-AGCCCATGTTGTAGCAAACC-3′) and TNF-a reverse (5′-
GAGGTACAGGCCCTCTGAT-3′).
.10. qPCR assay for cytokine expression and data analysis
PCR was performed on all cDNA samples to assess the quality
f the cDNA. The qPCR assay was performed for the expression
f pro- and anti-inﬂammatory cytokines. The qPCR reaction con-
isted of 5 l Power SYBR Green MasterMix (Applied Biosystems),
5 nM of forward and reverse primer and 500 ng template cDNA in
 10 l ﬁnal reaction volume. PCR was performed in a 7900HT Fast
eal-Time PCR System (Applied Biosystems). The initial steps were min  incubation at 50◦C followed by 10 min  incubation at 95◦C, the
emplate was  then ampliﬁed for 40 cycles under these conditions:
5 s incubation at 95◦C and 1 min  incubation at 60◦C. Samples were
ormalized using the expression of human 18 S rRNA. Data was  ana-ytokine (e.g. between zero and 2 g/ml of factor H and zero and 20 g/ml of factor
gniﬁcant).
lyzed using the RQ Manager Version 1.2.1 (Applied Biosystems). Ct
(cycle threshold) values for each cytokine target gene were calcu-
lated and the relative expression of each cytokine target gene was
calculated using the Relative Quantiﬁcation (RQ) value, using the
formula: RQ = 2−Ct for each cytokine target gene, and compar-
ing relative expression with that of the 18 S rRNA constitutive gene
product. Assays were conducted twice in triplicate.
2.11. Statistical analysis
Statistical analysis was performed using GraphPad Prism ver-
sion 6.0 (GraphPad Software). A 2-way ANOVA test was used to
compare the means of the cytokine targets between zero and
2 g/ml of factor H and zero and 20 g/ml of factor H for any sig-
niﬁcant differences in gene expression over the given time-points.
P values were computed, and graphs were compiled and analyzed.
9 nobio
3
3
t
b
v
d
M
i
H
b
1
b
i
f
r
c
c
3
w
b
(
s
a
o
m
b
t
b
d
b
f
c
X
3
m
c
d
T
a
5
(
b
w
r
b
f
c
h
3
o
u

s50 M.  Abdul-Aziz et al. / Immu
. Results
.1. Human factor H binds to mycobacteria
In our previous study, we showed that M.  bovis BCG was  able
o bind factor H (Carroll et al., 2009). Initial characterization of this
inding was performed in the presence of EDTA, as nearly all pre-
iously observed factor H binding is not divalent metal ion (M++)
ependent. Further investigations showed that factor H binding to
. bovis BCG and was higher in the presence of Ca2+/Mg2+ than
n the presence of EDTA. A concentration of 5–10 g/ml of factor
 was sufﬁcient to reach saturation of binding at the given num-
er of bacteria, which was well below the in vivo plasma level of
28–654 g/ml (Ansari et al., 2013) (Fig. 1(a). A 3- to 4-fold greater
inding of factor H was observed in the presence of Ca2+/Mg2+ than
n EDTA. This may  suggest at least 2 different types of binding site
or factor H, namely M++-dependent and M++-independent. Fluo-
escence microscopy shows binding of factor H to M. bovis BCG
ells; increasing signal intensity can be noticed with increasing
oncentrations of factor H (Fig. 1b).
.2. Competition assay showed C4BP binding to similar ligands
ith factor H on mycobacterial surface
C4BP was observed to bind to M.  bovis BCG and the degree of
inding was very similar in the presence of EDTA and of Ca2+/Mg2+
Fig. 2). No binding of C4BP was observed when C4BP depleted
erum was used as a control for assay speciﬁcity. A competitive
ssay conﬁrmed that C4BP competed with factor H for binding
n the mycobacterial cell surface (Fig. 3). The binding of C4BP to
ycobacteria was also observed to be dose-dependently inhibited
y factor H, suggesting that both complement proteins bound to
he same or overlapping ligands on mycobacteria.
Extensive afﬁnity chromatography experiments using immo-
ilised factor H and M.  bovis BCG lysates (in Triton X100) failed to
etect any protein/glycoprotein ligand(s) for factor H (not shown)
y SDS-PAGE analysis. This suggests that the mycobacterial ligands
or factor H may  not be proteinaceous. An alternative explanation
ould be that the mycobacterial ligand(s) is not solubilized by Triton
100.
.3. Factor H inhibits uptake of M.  bovis BCG by THP-1
acrophages
Following phagocytosis assay using PMA-differentiated THP-1
ells, CFU counts of M.  bovis BCG showed that factor H dose-
ependently inhibited mycobacterial uptake by THP-1 cells (Fig. 4).
he input number of mycobacteria (unchallenged with THP-1) was
bout 78 × 106 CFU/ml. From this number, 40 × 106 CFU/ml (about
0%) of mycobacteria were phagocytosed from the control well
untreated with factor H). The uptake by macrophage was reduced
y ∼60% (15 × 106 CFU/ml) when mycobacteria were incubated
ith a low dose of puriﬁed factor H (2 g/ml). The uptake was
educed by ∼ 80% (6 × 106 CFU/ml) when mycobacteria were incu-
ated with a higher dose of puriﬁed factor H (20 g/ml). Thus,
actor H, once bound to M.  bovis BCG, can interfere with phago-
ytosis, highlighting a non-complement related role for factor H in
ost-pathogen interaction.
.4. Factor H modulates cytokine responses during phagocytosis
f M.  bovis BCG by THP-1 macrophagesOur quantitative (qPCR) data revealed that there was  a broad
p-regulation by factor H of pro-inﬂammatory cytokines TNF-
, IL-1, and IL-6 (Fig. 5a, b and c), particularly at the initial
tage of macrophage uptake (15 min) which decreased graduallylogy 221 (2016) 944–952
towards the later stages of phagocytosis. It is well known that
macrophage activation by TNF- is particularly critical for killing
of intracellular mycobacteria and is a key mediator in granuloma
formation. In contrast, there was  an extensive down-regulation of
anti-inﬂammatory IL-10 and TGF- (Fig. 5d and e). The cytokine IL-
12 also appeared to be down-regulated (Fig. 5f), suggesting a likely
suppression of Th1 activated CD4+ T-cells, resulting in reduced
levels of IFN- production, a key cytokine important in activating
macrophages to kill intracellular mycobacteria and the recruitment
of immune cells during granuloma formation. Factor H, therefore
has a marked inﬂuence on the cytokines produced by macrophages,
which may  play an important role in shaping the adaptive immune
response during M. tuberculosis infection.
4. Discussion
We  have previously shown that human factor H can bind to M.
bovis BCG and that the bacterium can trigger antibody-independent
complement activation by all three pathways (Carroll et al., 2009).
However, very little is known about the role of individual comple-
ment proteins in tuberculosis infection, particularly complement
control proteins such as factor H. In the present study, our goal was
to further characterise the interactions of factor H with mycobacte-
ria, with a view to examining its possible role in the pathogenesis
of tuberculosis. Factor H has been shown to bind to a number of
microorganisms with probable roles in pathogenesis. This has been
particularly highlighted for N. meningitidis via structural charac-
terisation of the pathogen ligand and its binding site on factor H
(Schneider et al., 2009). The central premise in most studies is that
factor H is utilised by pathogens to evade complement attack, since
factor H is a downregulator of complement. However in the present
study, we  present data suggesting that factor H may have other
non-complement related functions in host-pathogen interaction
too, particularly in modulating and shaping the localisation of the
bacteria in tuberculosis infection.
We observe that human factor H binds to M.  bovis BCG (Fig. 1a
and b). Binding is dose dependent; saturation of binding is observed
at 5–10 g/ml of factor H, which is far below the plasma level of
128–654 g/ml (Ansari et al., 2013). Binding is greater in the pres-
ence of divalent metal ions (Ca2+ and Mg2+) than in the presence
of EDTA. This has not been previously observed in the binding of
factor H to microorganisms and in most other ligands, such bind-
ing is generally divalent metal ion-independent. C1q is known to
compete with factor H for binding to a range of ligands (Kishore
and Sim, 2012), whilst 2-glycoprotein 1, a structural homologue
of factor H, behaves similarly to factor H in binding anionic phos-
pholipids (Kertesz et al., 1995). Separate binding tests with C1q
and 2-glycoprotein 1 show that both bind to M.  bovis BCG (Carroll
et al., 2009), but neither competes with factor H for binding to the
bacterium. However, C4BP was  also shown to bind to the mycobac-
teria (Fig. 3), and factor H competed signiﬁcantly with C4BP binding
(Fig. 4), suggesting that both complement proteins may  bind to the
same or overlapping mycobacterial ligands. C4BP is also a close
structural and functional homologue of factor H and is also known
to bind to several bacteria (Blom et al., 1999; Pietikainen et al.,
2010).
The recruitment of factor H by mycobacteria may  be particu-
larly critical in the initial stages of tuberculosis infection, when
after inhalation, the ﬁrst host cell M.  tuberculosis encounters is the
alveolar macrophage. In the present study, we show that coat-
ing of M. bovis BCG with factor H signiﬁcantly inhibits uptake
of the bacterium by THP-1 macrophages (Fig. 4). In vivo, alve-
olar macrophages phagocytose mycobacteria, but ultimately fail
to destroy them, and in the process produce important chemoat-
tractants that recuit inﬂammatory cells such as neutrophils, -T
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ells, monocyte-derived macrophages and NK cells that encourages
nﬂammation and tissue remodelling (Feng et al., 2006). During
nteraction and phagocytosis of factor H-treated M.  bovis BCG by
HP-1 cells, there was a striking difference in the levels of pro-
nd anti-inﬂammatory cytokines produced by the THP-1 cells (Fig.
). TNF- expression was heightened signiﬁcantly in the presence
f factor H, particularly in the early stages of phagocytosis. This
nhanced pro-inﬂammatory response was also mirrored in ele-
ated levels of IL-1 and IL-6 cytokines. IL-1 is a potent cytokine
equired for host resistance to tuberculosis (Mayer-Barber et al.,
010), whilst IL-6 is required for an optimal T cell response against
.  tuberculosis infection (Leal et al., 1999). In contrast, there was
 downregulation of IL-12 by factor H, which in vivo may  down-
egulate the Th1 response and the production of IFN- reducing
nﬂammation. The cytokines IL-10 and TGF- were also observed to
e downregulated signiﬁcantly in the presence of factor H, suggest-
ng the suppression of the anti-inﬂammatory cytokine response.
aken together, these data may  mirror the early inﬂammatory pro-
esses in vivo, which results in granuloma formation, a lesion of
nﬂammatory mononuclear cell inﬁltrate that cordons off M. tuber-
ulosis infection and limits its growth, but also provides a niche for
he pathogen to persist as a latent infection. TNF- is a key medi-
tor in granuloma development; both TNF- and IFN- accelerate
he recuitment of cells in the granuloma (Smith et al., 1997). Factor
 may, therefore, play a role in promoting the pro-inﬂammatory
ytokine responses that results in granuloma formation and its
aintenance. It is known that in order for a protective home-
static granuloma to be maintained, a balance of inﬂammation
s required, primarily the Th1/Th2 balance (Ehlers and Schaible,
012). This is driven by the balance in IFN-/TNF- versus IL-4/IL-
0/TGF- within the granuloma. It is possible, from the data in the
resent study, that factor H can play a role in perpetuating this
alance. Within the granuloma, M.  tuberculosis is sequestered intra-
ellularly and undergoes metabolic adaption limiting its growth. It
s unknown if any complement proteins reside within the gran-
loma, but it is likely that signiﬁcant quantities of factor H are
resent. Factor H expression is also enhanced in monocytes by IFN-
 (Schwaeble et al., 1987). Therefore factor H, if resident within the
ranuloma, may  be a key signalling molecule that plays a role in
reventing Th1/Th2 imbalance, which ultimately results in gran-
loma necrosis, M.  tuberculosis recrudescence and growth, which
s precipitated by CD4+ T cell activation (Dannenberg, 1991). It
ay  therefore not be surprising that innate immune molecules
ould support granuloma/latency, targetting macrophages instead
f allowing T cell involvement. Since macrophages can locally pro-
uce complement proteins such as C1q, they may  be the primary
ource for factor H in the granuloma.
The suppression of IL-10 and TGF- by factor H may  promote
ycobacterial clearance by the host during the early stages of
.  tuberculosis infection, as discussed below. Upon phagocyto-
is of M.  tuberculosis, alveolar macrophages produce IL-10 (Shaw
t al., 2000), which M.  tuberculosis may  exploit to circumvent
nti-microbial responses. IL-10 has been shown to block phago-
ome maturation, which facilitates M.  tuberculosis survival (O’Leary
t al., 2011). Furthermore, IL-10 produced during phagocytosis
ay  also block antigen presentation via downregulation of the
ajor histocompatibility complex. IL-10 has also been implicated
n down-regulating dentritic cell activation (Demangel et al., 2002),
hich leads to a weakened Th1 response with increased mycobac-
erial growth (Tian et al., 2005). Clinically, IL-10 and TGF- have
lso been shown to be elevated in the lungs of active tuberculosis
atients, indicating a limited immune response to M. tuberculosis
nd a role in pathogenesis and disease progression (Gong et al.,
996). Thus, factor H-inﬂuenced phagocytosis of mycobacteria may
ct to diminish these evasion mechanisms, enhancing clearance inlogy 221 (2016) 944–952 951
the early stages of infection and facilitating a protective response
against mycobacterial infection.
The supression of IL-12 by factor H may  be a direct result of the
reduction in phagocytosis of M. bovis BCG and poor antigen presen-
tation, which would lead to a downregulation in Th1 response and
the mobilization of CD4+ T cells, producing IFN-. This would be
particularly crucial in contributing to the Th1/Th2 balance within
the protective granuloma, where studies have shown that T-cell
activation can kick start granuloma necrosis (Ehlers et al., 2001).
The mycobacterial ligand for factor H is unknown, but afﬁnity
chromatography suggested that it may  not be a protein or glyco-
protein. Given the substantial and complex lipid composition of the
mycobacterial cell wall, the ligand may  be lipid in nature and may
be comparable to known interactions of factor H with lipid A and
anionic phospholipids (Kishore and Sim, 2012).
The quantity of factor H in the lungs of healthy individuals is
unknown. It is likely to be low, but would probably increase upon
inﬂammation, as observed in lung cancer cells (Ajona et al., 2004)
and would probably be produced locally by phagocytes such as the
alveolar macrophage or alveolar epithelium (Ajona et al., 2007).
It would be also be interesting to determine the concentation of
factor H in immunocompromised (e.g. HIV-infected) individuals as
well as those with chronic obstructive pulmonary disease (COPD) or
underlying lung disease e.g. asthma. The local levels of factor H may
be a key element in inﬂuencing opportunistic infections. Similarly,
it is also worth considering the role of factor H in extrapulmonary
TB, since extracellular M. tuberculosis in the blood would come into
contact with copious amounts of factor H, potentially facililating
the dissemination of TB infection to other organs.
Intriguingly, factor H has been identiﬁed previously as having
a possible role in granuloma-like pathology. During Echinococcus
granulosus infection, the parasite forms a hydatid cyst and is present
in mammals and humans in a condition called hydatid disease,
that is analoguous to a latent infection, surviving in the host for
decades. It has been found that the cyst wall binds substantial
amounts of factor H, effectively surrounding the organism with a
high concentration of factor H (Diaz et al., 1997). During this chronic
infection, a granuloma-like layer forms around the cyst wall, con-
taining multinucleated giant cells and macrophages which take on
osteoclast-like properties (Diaz et al., 2011, 2000); factor H medi-
ates this host-pathogen interaction.
In conclusion, the data in this study suggest that factor H
is involved in modulating the host-pathogen interaction in the
early stages of tuberculosis infection. The consequences are that
factor H may  have a dual role: ﬁrstly, the enhancement of clear-
ing of mycobacterial infection, by downplaying pathogen immune
evasion strategies via upregulating the cellular immune response
against infection; and secondly by promoting the formation and
maintenance of the protective granuloma. This study provides
insights into previously unknown involvement of complement reg-
ulatory protein factor H in shaping the cellular immune response
against mycobacteria. Further studies are required to fully char-
acterise the nature and extent of involvement of factor H in
tuberculosis pathogenesis, particularly in the early stages of gran-
uloma formation and the maintainance of immune balance. Should
a signiﬁcant role be conﬁrmed for factor H in this intricate host-
pathogen stand-off, then this will provide a new rationale for the
design of therapies against this most complex of diseases. Clearly,
this study needs further investigation using pathogenic M.  tubercu-
losis.None.
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